Sun Pharmaceutical Industries Ltd
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- Public
- Established
- 1983-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sunpharma.com
Clinical Trials
98
Active:6
Completed:67
Trial Phases
4 Phases
Phase 1:7
Phase 2:4
Phase 3:42
+1 more phases
Drug Approvals
75
PHILIPPINES:52
NMPA:22
FDA:1
Drug Approvals
Octreotide Acetate Injection
- Product Name
- 启文
- Approval Number
- 国药准字HJ20140908
- Approval Date
- Sep 30, 2024
NMPA
Fexofenadine Hydrochloride Tablets
- Product Name
- 阿特拉
- Approval Number
- 国药准字HJ20170080
- Approval Date
- Jan 11, 2022
NMPA
Fexofenadine Hydrochloride Tablets
- Product Name
- 阿特拉
- Approval Number
- 国药准字HJ20170079
- Approval Date
- Jan 11, 2022
NMPA
Fexofenadine Hydrochloride Tablets
- Product Name
- 阿特拉
- Approval Number
- 国药准字HJ20170078
- Approval Date
- Jan 11, 2022
NMPA
Fexofenadine Hydrochloride Tablets
- Product Name
- 阿特拉
- Approval Number
- 国药准字HJ20170077
- Approval Date
- Jan 11, 2022
NMPA
Cetirizine Hydrochloride Tablets
- Product Name
- 赛特赞
- Approval Number
- 国药准字HJ20170009
- Approval Date
- Dec 14, 2021
NMPA
Olanzapine Orally Disintegrating Tablets
- Product Name
- 奥氮平口崩片
- Approval Number
- 国药准字HJ20210017
- Approval Date
- Mar 23, 2021
NMPA
- Prev
- 1
- 2
- 3
- Next
Clinical Trials
Distribution across different clinical trial phases (76 trials with phase data)• Click on a phase to view related trials
Phase 3
42 (55.3%)Not Applicable
23 (30.3%)Phase 1
7 (9.2%)Phase 2
4 (5.3%)No trials found
News
Sun Pharma's Halol Facility Receives Eight FDA Observations Following Latest Inspection
The US FDA issued eight observations to Sun Pharma's Halol manufacturing facility in Gujarat following a Good Manufacturing Practices inspection conducted from June 2-13, 2025.
Sun Pharma Invests $25 Million in Pharmazz, Expanding Stake to 22.7% and Securing Key Drug Rights
Sun Pharmaceutical Industries Ltd has announced a strategic $25 million investment in US-based Pharmazz Inc, increasing its ownership stake to 22.7% in the biopharmaceutical company.
U.S. Court Ruling Clears Path for Sun Pharma's Alopecia Drug Leqselvi Launch
The U.S. Court of Appeals for the Federal Circuit has vacated a preliminary injunction against Sun Pharma, allowing the company to proceed with launching Leqselvi (deuruxolitinib) for alopecia areata in the American market.